Abel Hall LLC’s PTC Therapeutics PTCT Stock Holding History

Abel Hall LLC’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$419K	Buy	5,134 +572	+13%	+$41.3K	0.07%	309
2026 Q1	$311K	Buy	+4,562	New	+$323K	0.07%	394

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Abel Hall LLC's PTCT Position: Q2 2026 in Review

Abel Hall LLC increased its PTC Therapeutics (PTCT) stake by 13% in Q2 2026, buying an estimated $41.3K and bringing the position to 5,134 shares worth $419K. The position accounts for 0.07% of the portfolio, ranked #309.

Abel Hall LLC first reported a position in PTCT in Q1 2026 and has held it in 2 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Abel Hall LLC held 5,134 shares of PTC Therapeutics worth $419K as of Q2 2026.
Abel Hall LLC bought 572 PTC Therapeutics shares in Q2 2026, an estimated $41.3K.
PTC Therapeutics made up 0.07% of Abel Hall LLC's portfolio in Q2 2026, its #309 holding.
Abel Hall LLC first reported a position in PTC Therapeutics in Q1 2026 and has held it in 2 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.